FDA sends warning letters to 7 foreign drugmakers; EMA sets rules for making drugs in transgenic animals;

> The FDA has sent warning letters to 7 companies in China, South Korea, India and France informing them that they have been found importing drugs into the U.S. without being registered. FDA warnings

> In an effort to be more self-sufficient in drugmaking, India intends to reduce its dependence on drugs and APIs manufactured in China. Story

> The FDA has sent out an alert about Reumofan Plus, a Mexican OTC supplement that has shown up in the U.S. and has caused adverse reactions because it contains prescription drugs. FDA release

> AMRI's ($AMRI) Burlington plant will produce sterile pre-filled syringes of a formulated collagen-based product for Cardium Therapeutics and its subsidiary, Tissue Repair Co. Item

> Drug manufacturers in Pakistan are arguing with the government over tax relief for raw materials. Story

And Finally... Six years after the first drug manufactured in transgenic goats was approved in Europe, the European Medicines Agency has published draft guidelines on how to insure quality APIs in transgenic animals. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.